Advertisement

Topics

Search Results for "Pharmaceutical Company Organization Chart"

21:30 EDT 29th June 2016 | BioPortfolio

Matching Channels

Contract Research Organization news

A contract research organization, also called a clinical research organization, (CRO) is a service organization that provides support to the pharmaceutical and biotechnology industries in the form o...

MediciGlobal is a specialty patient recruitment-retention organization serving the clinical trials industry

MediciGlobal is a specialty patient recruitment-retention organization serving the clinical trials industry. For more than two decades, the company has led the industry in developing innovative p...

Connecticut

Connecticut, a state in the north-east corner of the US is a hub for biotechnology companies. There are over 100 high-quality companies with global markets based in Connecticut. In 2004, Connectic...

Visual acuity

Visual acuity (VA) is acuteness or clearness of vision, which is dependent on the sharpness of the retinal focus within the eye and the sensitivity of the interpretative faculty of the brain. Visu...

Medtronic

With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...

Matching News

Could a brain 'growth chart' spot attention problems early? New study suggests so

Want to know if your child's height and weight are on track? Check the growth chart that the doctor gives you after each yearly checkup.

BRIEF-Celyad CHART-1 Phase III trial shows no significant difference on primary endpoint

* Announces results CHART-1 Phase III clinical trial evaluating c-cure cell therapy

Brain Imaging 'Growth Chart' May Flag Early Attention Problems

Children with ADHD show distinct patterns in brain maturation that are evident on neuroimaging, suggesting the potential to develop a neurologic growth chart similar to other types of growth charts. ...

Mixed results for Celyad CHART-1 Phase III trial evaluating C-Cure cell therapy

Belgian biotech firm Celyad today announced mixed headline results for CHART-1, its European Phase III…

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2016 Global Healthcare Conference

Monday, June 6th 2016 at 12:00pm UTC SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapie...

Lannett Company (LCI) - Investment Analysts' Weekly Ratings Updates

According to Zacks, "Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under it...

#jobs #lifescience Fred Hutch: Clinical Chart Review Specialist

// Fred Hutch: Job ID 6825 Type Temporary Part-Time Company Fred Hutchinson Cancer Research Center Location US – WA – Seattle Overview Cures Start Here. At Fred Hutchinson Cancer Research ...

Pharmaceutical services firm Medpace readies IPO-sources

April 21 (Reuters) - Pharmaceutical services company Medpace Inc is preparing for a potential initial public offering in the United States that could value the pharmaceutical contract research organiz...

Matching PubMed Articles

Assessing Information from Pharmaceutical Company Representatives.

A Legal Test for the Pharmaceutical Company Practice of "Product Hopping".

Quantitative determination of the antidepressant vortioxetine and its major human metabolite in plasma.

Vortioxetine is a novel antidepressant that has been developed in a joint partnership between H. Lundbeck A/S and the Takeda Pharmaceutical Company, Ltd.

Inadequate documentation of urinary tract infection symptoms in the medical chart.

We evaluated symptom documentation for 312 inpatients with bacteriuria by comparing information found in the chart with that obtained prospectively from the medical and nursing team caring for the pat...

Continuous hyperfractionated accelerated radiotherapy - Escalated dose (CHART-ED): A phase I study.

Patients who present with locally advanced inoperable non-small cell lung cancer (NSCLC) may be suitable for radical radiotherapy. A randomised trial of 563 patients compared CHART and conventional ra...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement